https://doi.org/10.4081/monaldi.2021.1816
The initial experience of COVID-19 vaccination from a tertiary care centre of India
Submitted: February 23, 2021
Accepted: March 19, 2021
Published: March 31, 2021
Accepted: March 19, 2021
Abstract Views: 4652
PDF: 2476
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor
Drugs Controller General of India (DCGI) has approved the Bharat biotech vaccine against COVID-19, which is a locally manufactured inactivated vaccine named ''COVAXIN'' in collaboration with the Indian council of medical research (ICMR) on 3rd January 2021 for emergency use along with the "Covishield" Oxford-AstraZeneca vaccine manufactured locally by the Serum Institute of India...
*The Safdarjung COVID-19 Vaccination group:
KR Meena (Professor, Paediatrics), U Venkatesh (Assistant Professor, Community Medicine), Pushpa Kumari (Associate Professor, Medicine), Sonal Burman (Specialist, Medicine), Neeraj Kumar Gupta (Professor and Head, Pulmonary Medicine), Nitesh Gupta (Assistant Professor, Pulmonary Medicine), Rohit Kumar (Assistant Professor, Pulmonary Medicine), Swetabh Purohit (Senior resident, Pulmonary Medicine), Arjun Ramaswamy (Senior resident, Pulmonary Medicine)
Ministry of Health and Family Welfare. Press statement by the Drugs Controller General of India (DCGI) on restricted emergency approval of COVID-19 virus vaccine. Jan 3, 2021. Accessed: January 5, 2021. Available from: https://pib.gov.in/PressReleseDetail.aspx?PRID=1685761
Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 2021;21:39-51.
DOI: https://doi.org/10.1016/S1473-3099(20)30831-8
Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv 2020.12.21.20248643.
DOI: https://doi.org/10.1101/2020.12.21.20248643
The Hindu [Internet]. Coronavirus. Covaxin efficacy is 81%, works against variants. Accessed: 18 March 2021. Available from: Downloaded from https://www.thehindu.com/sci-tech/health/bharat-biotech-says-covid-19-vaccine-shows-81-interim-efficacy/article33980224.ece
Government of India. Operational Guideline COVID-19 Vaccines [Internet]. New Delhi; 2021. Accessed: 22 February 2021. Available from: https://www.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf
The Times of India [Internet]. Covid-19: India vaccinates 54.7% healthcare workers registered on CoWin platform. Accessed: 22 February 2021. Available from: https://timesofindia.indiatimes.com/india/covid-19-india-vaccinates-54-7-healthcare-workers-registered-on-cowin-platform/articleshow/80725869.cms
WHO. Classification of AEFIS. Accessed: 22 February 2021. Available from: https://vaccine-safety-training.org/classification-of-aefis.html
How to Cite
Srivastava, RK, Pranav Ish, and *Safdarjung COVID-19 Vaccination group. 2021. “The Initial Experience of COVID-19 Vaccination from a Tertiary Care Centre of India”. Monaldi Archives for Chest Disease 91 (4). https://doi.org/10.4081/monaldi.2021.1816.
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Neeta Singla, Amitesh Gupta, U.K. Khalid, Ravindra Kumar Dewan, Rupak Singla, Clinical profile, risk factors, disease severity, and outcome for COVID-19 disease in patients with tuberculosis on treatment under the National Tuberculosis Elimination Program: a cohort of 1400 patients , Monaldi Archives for Chest Disease: Early Access
- Megha Hegde, Saurav Raj, Dhananjay Tikadar, Sanatkumar B Nyamagoud, Unveiling vaccine safety: a narrative review of pharmacovigilance in India’s COVID-19 vaccination , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Amrutha S, Komaldeep Kaur, Deepak Aggarwal, Mandeep Kaur Sodhi, Shivani Jaswal, Varinder Saini, Serial evaluation of antibody titres in patients recovered from COVID-19 and their correlation with disease severity , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- Frederico Ribeiro Neto, Juliane Machado Marques, Matheus Brasiliano da Paz, Eduardo Boiteux Uchôa Cavalcanti, Rodrigo Rodrigues Gomes Costa, Sit-to-stand test and handgrip strength in men and women with post-COVID-19 syndrome without invasive ventilator support: insights from a Brazilian observational study , Monaldi Archives for Chest Disease: Vol. 94 No. 3 (2024)
- Unnati Desai, Ketaki Utpat, Aravind Raj, The impact of the COVID-19 pandemic on the profile of interstitial lung disease presenting to the pulmonary medicine department of a tertiary care center in western India , Monaldi Archives for Chest Disease: Early Access
- Halil Yanardag, Cuneyt Tetikkurt, Muammer Bilir, Clinical and prognostic significance of muscle biopsy in sarcoidosis , Monaldi Archives for Chest Disease: Vol. 88 No. 1 (2018)
- Angelica Cersosimo, Mattia Di Pasquale, Gianmarco Arabia, Marco Metra, Enrico Vizzardi, COVID myocarditis: a review of the literature , Monaldi Archives for Chest Disease: Vol. 94 No. 4 (2024)
- C. Incorvaia, F. Frati, P. Puccinelli, G.G. Riario-Sforza, S. Dal Bo, Dose dependence of efficacy and safety of subcutaneous immunotherapy , Monaldi Archives for Chest Disease: Vol. 65 No. 1 (2006): Pulmonary series
- Deldar Morad Abdulah, Abbas Muhammed Sadiq Mirza, Receiving COVID-19 vaccine, hospitalization, and outcomes of patients with COVID-19: A prospective study , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Neeti Rustagi, Yachana Choudhary, Shahir Asfahan, Kunal Deokar, Abhishek Jaiswal, Prasanna Thirunavukkarasu, Nitesh Kumar, Pankaja Raghav, Identifying psychological antecedents and predictors of vaccine hesitancy through machine learning: A cross sectional study among chronic disease patients of deprived urban neighbourhood, India , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
You may also start an advanced similarity search for this article.
